Accuray Incorporated (ARAY) by event type
ARAY moves most on analyst downgrades — a median of -0.20% at 30 minutes across 14 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the ARAY overview →
How ARAY reacts across 2 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades 1,887 of 2,603 | 14 | -0.20% | 36% | -3.46% |
| Rating reiterations 1,506 of 3,522 | 12 | +0.01% | 50% | +1.85% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 4 further classes were observed with fewer than 10 measured events and are not published.
That’s how ARAY usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst downgrades → · Rating reiterations → · ARAY overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CRISPR Therapeutics AG - Common Shares (CRSP) | 291 | +0.10% | 53% |
| Seres Therapeutics, Inc. (MCRB) | 290 | -0.23% | 46% |
| Chemed Corp (CHE) | 288 | +0.02% | 53% |
| Fate Therapeutics, Inc. (FATE) | 287 | -0.76% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.